Ferring Pharmaceuticals has one less barrier to uptake of its standardized fecal microbiota transplant treatment for recurrent Clostridioides difficile following US Food and Drug Administration finalization of a 2016 guidance that narrows the circumstances under which the agency will exercise enforcement discretion and permit the use of unapproved products.
Ferring’s Rebyota, received a favorable FDA advisory committee review in September, in large part due to the preference of agency...







